摘要:
This invention provides methods of lowering cholesterol, delaying the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia. These methods involve administering to or expressing in a mammal, an apoE polypeptide or nucleic acid that, when administered to or expressed in a mammal, lowers the total serum cholesterol level without inducing hypertriglyceridemia.
摘要:
A pharmaceutical composition for once per day administration to alter lipids in an individual without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, said pharmaceutical composition comprising an effective lipid altering amount of nicotinic acid in an extended release form and an effective lipid altering amount of an HMG-CoA reductase inhibitor.
摘要:
There is disclosed a pharmaceutical combination for lessening or preventing any flush reaction caused by nicotinic acid therapy, the combination comprising nicotinic acid and a nonsteroidal anti-inflammatory drug in an amount effective to inhibit or reduce prostaglandin D 2 (PGD 2 ) synthesis.
摘要:
This invention provides methods of lowering cholesterol, delaying the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia. These methods involve administering to or expressing in a mammal, an apoE polypeptide or nucleic acid that, when administered to or expressed in a mammal, lowers the total serum cholesterol level without inducing hypertriglyceridemia.
摘要:
Méthode permettant de prévenir ou de soulager la migraine consistant à administrer une dose pharmaceutiquement efficace d'une substance bloquant la dégranulation des mastocytes juste avant ou pendant la phase prodromique de la migraine en l'absence d'un analgésique. La substance peut également être administrée en même temps qu'un stimulant du système nerveux central.
摘要:
An improved breath coordinated inhaler (10) is provided for administering medication to a patient in aerosol form for respiratory inhalation therapy. The improved inhaler (10) comprises a compact housing (18) adapted to receive and support a medication canister (12), including a valve assembly (14) actuated to deliver a dosage of the medication in aerosol form. The housing (18) includes a plunger mounted at a first end thereof for displacing the canister against a spray nozzle (24) located at a second end of the housing to actuate the valve assembly (14), and deliver the medication through a mouthpiece (26) to the patient. The plunger (36) is associated with a seal arrangement for venting the housing (18) when the plunger is depressed to allow the patient to draw in air in timed relation to the medication delivery, and to substantially reseal the housing (18) against ingress of contaminants when the plunger (36) is released.
摘要:
An improved breath coordinated inhaler (10) is provided for administering medication to a patient in aerosol form for respiratory inhalation therapy. The improved inhaler (10) comprises a compact housing (18) adapted to receive and support a medication canister (12), including a valve assembly (14) actuated to deliver a dosage of the medication in aerosol form. The housing (18) includes a plunger mounted at a first end thereof for displacing the canister against a spray nozzle (24) located at a second end of the housing to actuate the valve assembly (14), and deliver the medication through a mouthpiece (26) to the patient. The plunger (36) is associated with a seal arrangement for venting the housing (18) when the plunger is depressed to allow the patient to draw in air in timed relation to the medication delivery, and to substantially reseal the housing (18) against ingress of contaminants when the plunger (36) is released.
摘要:
An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic substantially immediately prior to each periodic physiological loss of consciousness.